TrialAnnals of hematology2024

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Tiziano Barbui et al.PubMed ↗Publisher ↗

No numbers read from the abstract.